Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)

Main Article Content

April W. Armstrong
University of Southern California, Los Angeles, CA, USA

Mark Lebwohl
Icahn School of Medicine at Mount Sinai, New York, NY, USA

Jerry Bagel
Psoriasis Treatment Center of New Jersey, East Windsor, NJ, USA

Todd Schlesinger
Clinical Research Center of the Carolinas, Charleston, SC, USA

Subhashis Banerjee
Bristol Myers Squibb, Princeton, NJ, USA

Renata M. Kisa
Bristol Myers Squibb, Princeton, NJ, USA

Thomas Scharnitz
Bristol Myers Squibb, Princeton, NJ, USA

Kim Hoyt
Bristol Myers Squibb, Princeton, NJ, USA

Bruce Strober
Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, USA

Keywords

Deucravacitinib, psoriasis, tyrosine kinase 2, phase 3 clinical trial, efficacy, apremilast

References

1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

2. Wrobleski ST et al. J Med Chem. 2019;62:8973-8995.

3. SOTYKTUTM (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022.

4. Armstrong AW, et al. J Am Acad Dermatol. 2023;88:29-39.

5. Strober B, et al. J Am Acad Dermatol. 2023;88:40-51.

6. Warren RB, et al. Presented at the EADV 30th Congress; September 29-October 2, 2021.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.120

Article Details

How to Cite
Armstrong, A. W., Lebwohl, M., Bagel, J., Schlesinger, T., Banerjee, S., Kisa, R. M., Scharnitz, T., Hoyt, K., & Strober, B. (2023). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI). SKIN The Journal of Cutaneous Medicine, 7(2), s120. https://doi.org/10.25251/skin.7.supp.120
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Posters from 2023 WCH Dermatology Conference: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>